All News

Findings in Hypertension, published by the American Heart Association, suggest a need to identify those at early risk of dementia.

Wednesday marked the start of the 116th Congress, as Democrats took charge of the House of Representatives for the first time since 2011, and the new chairman of the Energy and Commerce Committee announced 3 hearings about the Affordable Care Act (ACA), climate change, and the Trump administration’s immigration policies.

A review of thousands of FDA inspection records, recalls, warning letters, and lawsuits showed how drugs that are poorly manufactured or contaminated can reach patients; biosimilars have the potential to deliver substantial savings to the healthcare system, but only insofar as they are adopted and used in clinical practice; Maine’s new Democratic Governor, Janet Mills, ordered the state to implement Medicaid expansion with an executive order, calling for state health officials to make the necessary changes and work with the Trump administration.

January 4 marks the anniversary of the Orphan Drug Act, which was enacted in 1983. Since the law was passed, it has successfully encouraged more orphan drug development, but some now say drug makers are manipulating the system and the incentives need to be revisited.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Hospitals that are participating in Medicare’s mandatory bundled payment model for hip and knee replacements reported a decrease in spending per episode of $812 compared with control hospitals not participating in the Comprehensive Care for Joint Replacement (CJR) program.

Patients with a history of migraine are more likely to develop spontaneous coronary artery dissection at a younger age, have depression, and post-SCAD chest pains compared with patients without a migraine history, according to the results of a recent study.

The year 2019 will finally be when the healthcare industry, particularly payers and providers, finally begins to catch up to other industries in terms of giving the consumer what they want.

A phase 1 trial by showed that decitabine with ruxolitinib was generally well tolerated and displayed promising clinical efficacy in patients with accelerated or blast-phase myeloproliferative neoplasms (MPN-AP/BP).

As expected, California and 16 other states defending the Affordable Care Act (ACA) in a federal lawsuit announced they will appeal last month’s ruling by a Texas judge that declared the ACA unconstitutional.

Assessing the alternation of first-line antibiotics to avoid antibiotic resistance, researchers have determined that the strategy results in an increase in heterogeneity without increasing mortality.

Bristol-Myers Squibb (BMS) announced that it will be acquiring Celgene for $74 billion; Congress has confirmed the Trump administration's nominees for science advisor and drug czar; and drugmakers kicked off 2019 with drug price hikes.

An evaluation of cognitive function measurements, performance in daily activities, and the perception of cognitive functions in patients with multiple sclerosis (MS) found caregiver perceptions more closely correlate with the test measurements than patient perceptions.

The FDA has approved Stemline Therapeutics’ tagraxofusp-erzs (Elzonris), the first drug approved to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients aged 2 years or older.

Quality of life (QOL) in at-risk individuals starting pre-exposure prophylaxis (PrEP) for HIV prevention is similar to that in the general population and is maintained over time.

A woman's risk of later pelvic floor disorders is strongly associated with how her first infant is delivered, according to a recent study.

The health insurance industry cautioned the Trump administration against allowing health reimbursement accounts (HRAs) to be used to purchase short-term limited duration health plans, in comments submitted regarding a proposed rule change.

While low-grade adverse events may not be providers’ primary reporting focus, accumulated low-level toxicities have the potential to reduce patients’ quality of life.

The federal judge who ruled last month that the Affordable Care Act (ACA) was invalid issued an order over the weekend that the law will remain in effect pending appeal; pharmacies and businesses with pharmacies in New York City will no longer be allowed to sell cigarettes and other tobacco products; a federal judge has blocked the administration's cut to the 340B program.

This year, The American Journal of Managed Care® asked readers for the first time who they thought was the most influential person in healthcare. We provided some options in the poll, but we also gave readers the opportunity to write in answers, which resulted in answers like Steve Jobs of Apple, who passed away in 2011.

Here are the top 5 articles for the month of December.

The Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, which reauthorizes a sickle cell disease prevention and treatment program and provides grants for research, surveillance, prevention, and treatment of heritable blood disorders, has passed Congress and been signed into law.

Patients with allergies to birch pollen who took drops of birch pollen extract under the tongue for 3 to 6 months were able to reduce their symptoms and improve their quality of life.

A genetic risk variant, rs7665090G, located near NFKB1, on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis (MS), according to the results of a recent study.

Children with Hodgkin lymphoma who are treated during childhood and survive to adulthood have higher incidence rates of breast, lung, colorectal, and thyroid cancer than the general population, according to a recent study.

As the US healthcare system continues to go through major shifts in policy and care delivery, 2018 saw several trends that remained prevalent throughout the year and will likely have significant implications for 2019.

Patients with multiple sclerosis (MS) who are stable on an interferon β (INFβ) should remain on that therapy rather than switching to another INFβ, according to a study in ClinicoEconomics and Outcomes Research.